stockportfolio.pro
Smith & Nephew plc (SNN)
Healthcare · Medical Devices · NYSE
Smith & Nephew plc revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $5.21B | $5.55B | $5.81B | $6.16B |
| Gross profit | $3.67B | $3.82B | $4.05B | $4.19B |
| Net income | $223.00M | $263.00M | $412.00M | $625.00M |
| Net margin | 4.3% | 4.7% | 7.1% | 10.1% |
Source: Smith & Nephew plc SEC filings (10-K).
What growth is priced into SNN stock?
At today's market cap of $12.94B, Smith & Nephew plc is priced for free-cash-flow growth of about 4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $852.00M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Smith & Nephew plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SNN in your portfolio →
Smith & Nephew plc financial history by metric
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Smith & Nephew plc — frequently asked questions
What is Smith & Nephew plc's revenue?
Smith & Nephew plc (SNN) reported revenue of $6.16B for fiscal year 2025, up 6.1% from the prior year, according to its SEC filings.
Is Smith & Nephew plc profitable?
Yes. SNN earned net income of $625.00M in fiscal 2025, a net margin of 10.1%.
What is SNN's P/E ratio?
Smith & Nephew plc trades at a price-to-earnings ratio of about 21.3 based on the latest data in our nightly-refreshed cache.
How fast is Smith & Nephew plc growing?
SNN's revenue grew at roughly 5.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Smith & Nephew plc have?
As of fiscal year 2025, SNN carried roughly $3.11B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Smith & Nephew plc's gross margin?
SNN's gross margin was 68.0% in fiscal 2025 — gross profit of $4.19B on revenue of $6.16B.
What is Smith & Nephew plc's market cap?
Smith & Nephew plc (SNN) has a market capitalization of about $12.94B, based on the latest data in our nightly-refreshed cache.
When does Smith & Nephew plc's fiscal year end?
SNN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SNN stock?
At today's market cap of $12.94B, Smith & Nephew plc is priced for free-cash-flow growth of about 4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $852.00M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Smith & Nephew plc's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.